• Xeris Pharmaceuticals Inc., of Austin, Texas, dosed its first subject in a Phase II study of G-Pen (glucagon injection) for severe hypoglycemia in people with diabetes. The product is designed as an alternative to glucagon emergency kits that contain glucagon as a dry powder in a sealed vial. The randomized, double-blind, three-way crossover trial will evaluate safety, tolerability and comparative pharmacokinetics and pharmacodynamics of G-Pen in 24 healthy volunteers.